AU2015316252A1 - Targeted delivery of hydrophilic drugs - Google Patents

Targeted delivery of hydrophilic drugs Download PDF

Info

Publication number
AU2015316252A1
AU2015316252A1 AU2015316252A AU2015316252A AU2015316252A1 AU 2015316252 A1 AU2015316252 A1 AU 2015316252A1 AU 2015316252 A AU2015316252 A AU 2015316252A AU 2015316252 A AU2015316252 A AU 2015316252A AU 2015316252 A1 AU2015316252 A1 AU 2015316252A1
Authority
AU
Australia
Prior art keywords
alkyl
straight chain
sulfonate
sulfate
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015316252A
Other languages
English (en)
Inventor
Igor Lokot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Double Bond Pharmaceuticals AB
Original Assignee
Double Bond Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Double Bond Pharmaceuticals AB filed Critical Double Bond Pharmaceuticals AB
Publication of AU2015316252A1 publication Critical patent/AU2015316252A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015316252A 2014-09-10 2015-09-09 Targeted delivery of hydrophilic drugs Abandoned AU2015316252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1400427-9 2014-09-10
SE1400427 2014-09-10
PCT/SE2015/000055 WO2016039678A1 (en) 2014-09-10 2015-09-09 Targeted delivery of hydrophilic drugs

Publications (1)

Publication Number Publication Date
AU2015316252A1 true AU2015316252A1 (en) 2017-03-09

Family

ID=55459328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015316252A Abandoned AU2015316252A1 (en) 2014-09-10 2015-09-09 Targeted delivery of hydrophilic drugs

Country Status (11)

Country Link
US (2) US10034838B2 (cg-RX-API-DMAC7.html)
EP (1) EP3191138B1 (cg-RX-API-DMAC7.html)
JP (1) JP6951971B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170054459A (cg-RX-API-DMAC7.html)
CN (1) CN107073129B (cg-RX-API-DMAC7.html)
AU (1) AU2015316252A1 (cg-RX-API-DMAC7.html)
CA (1) CA2958820A1 (cg-RX-API-DMAC7.html)
EA (1) EA033526B1 (cg-RX-API-DMAC7.html)
IL (1) IL250637A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017003049A (cg-RX-API-DMAC7.html)
WO (1) WO2016039678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426228A1 (en) * 2016-03-07 2019-01-16 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs to lung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
CN101134119A (zh) 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
GB2415904B (en) 2005-02-07 2006-10-25 Chiron Corp Preparing aldesleukin for pharmaceutical use
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
CN101327190B (zh) * 2008-07-29 2011-04-27 北京大学 一种供注射用的抗肿瘤长循环靶向脂质体
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
KR101728011B1 (ko) 2013-01-23 2017-04-20 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 덱스트란 메타크릴레이트 및 생체적합성 음이온성 고분자를 포함하는 생분해성 마이크로 비드 및 이의 제조방법

Also Published As

Publication number Publication date
EP3191138A4 (en) 2018-06-20
IL250637A0 (en) 2017-04-30
JP2017527593A (ja) 2017-09-21
JP6951971B2 (ja) 2021-10-20
EP3191138A1 (en) 2017-07-19
CA2958820A1 (en) 2016-03-17
EP3191138B1 (en) 2024-05-29
EA033526B1 (ru) 2019-10-31
US10034838B2 (en) 2018-07-31
MX2017003049A (es) 2017-05-23
WO2016039678A1 (en) 2016-03-17
US20170239192A1 (en) 2017-08-24
US20190046462A1 (en) 2019-02-14
KR20170054459A (ko) 2017-05-17
EP3191138C0 (en) 2024-05-29
CN107073129A (zh) 2017-08-18
CN107073129B (zh) 2021-10-15
US10973772B2 (en) 2021-04-13
EA201790272A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
Baig et al. Current status of nanomaterial-based treatment for hepatocellular carcinoma
Yang et al. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer
Morsy et al. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers
Fernandes et al. Nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid as a theranostic agent: evaluation of biodistribution and antitumor activity in experimental model
PT1863448E (pt) Novas composições de lipossomas
Wang et al. Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies
KR20130114240A (ko) 화학요법적 항종양 약물을 함유하는 나노입자
Li et al. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency
Zhu et al. Exogenous vitamin C boosts the antitumor efficacy of paclitaxel containing reduction-sensitive shell-sheddable micelles in vivo
Li et al. Construction and anti-tumor activities of disulfide-linked docetaxel-dihydroartemisinin nanoconjugates
Xu et al. A sequentially responsive and structure-transformable nanoparticle with a comprehensively improved ‘CAPIR cascade’for enhanced antitumor effect
Deepak et al. c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity
Xu et al. Selective self-induced stimulus amplification prodrug platform for inhibiting multidrug resistance and lung metastasis
CN114377141A (zh) 一种药物递送载体及其抗肿瘤应用
US10973772B2 (en) Targeted delivery of hydrophilic drugs
Li et al. Doxorubicin-loaded dextran-modified goldmag nanoparticles for targeting hepatocellular carcinoma
MXPA06010950A (es) Formulaciones en nano-particulas de compuestos de platino.
CN107233314B (zh) 一种具有双靶区同时递药效果的复合磷脂热敏脂质体及其制备方法和应用
Malhotra et al. Engineering cellular membrane for dual mode therapy using NIR responsive photosensitizer and reversible topoisomerase inhibition activity
EP3453390B1 (en) Polymerized drug-containing pharmaceutical composition
Rong et al. Polyphenol-based paclitaxel prodrug self-assembled nanoplatform for tumor synergistic therapy
Zhang et al. Transferrin-modified cancer cell member coating hypocrellin B-derived nanomaterials for enhanced photodynamic therapy efficacy in hepatocellular carcinoma
Wu et al. Biomimetic lipidic nanovectors for effective asparaginase supramolecule delivery
Shahin et al. Current development in vincristine nanoformulations
Chen et al. Nanotechnology: a better diagnosis and treatment strategy for brain tumour?

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period